Scientists Develop Novel Approach to Target Challenging Prostate Cancer Protein

In a groundbreaking study published in the Proceedings of the National Academy of Sciences, researchers at the University of Michigan have uncovered a promising new avenue for targeting prostate cancer by drugging a protein once deemed “undruggable.” Prostate cancer, a leading cause of cancer-related mortality among men in the United States, often involves a genetic rearrangement that fuses the TMPRSS2 and ERG genes. This fusion leads to the abnormal activation of the ERG protein, which in turn fuels tumor growth and metastasis.

Historically, ERG has been a challenging drug target because it lacks well-defined binding pockets, the usual footholds small molecule drugs latch onto. However, the research team has now identified a previously unknown ligandable site within a specific region of the ERG protein known as the PNT domain. This discovery paved the way for the development of a small molecule probe, PBITE-1, designed to selectively bind and inhibit ERG’s oncogenic activity.

The researchers synthesized and screened over 1,600 compounds to find molecules capable of engaging the PNT domain. Through iterative optimization, they developed PBITE-1, which effectively disrupts ERG’s interaction with other proteins critical for cancer progression. In preclinical models—including prostate cancer cell lines and human and murine organ systems—PBITE-1 induced cancer cell death and prevented invasive behavior, demonstrating tangible anti-tumor effects.

This breakthrough is particularly significant because current prostate cancer treatments predominantly target androgen receptors, which activate ERG gene fusions that spur tumor development. While androgen receptor inhibitors can temporarily halt cancer growth, tumors often develop resistance, and patients endure severe side effects. PBITE-1 offers a new therapeutic strategy by directly targeting ERG, potentially circumventing resistance mechanisms associated with hormonal therapy.

Lead investigator Dr. Arul Chinnaiyan, who was instrumental in first identifying the TMPRSS2-ERG fusion, emphasized the importance of this discovery: “Our findings establish ERG as a druggable oncogenic driver, opening the door for personalized treatment strategies tailored to specific prostate cancer subtypes.” While PBITE-1 itself is not yet ready for clinical use, it represents a crucial proof of concept demonstrating that disrupting ERG function is feasible.

The study not only sheds light on the molecular intricacies of prostate cancer but also exemplifies how identifying previously hidden target sites on ‘undruggable’ proteins can propel therapeutic innovation. As drug development efforts continue, PBITE-1 and similar compounds may redefine treatment paradigms, offering hope for improved outcomes in one of men’s most deadly cancers.